Merck and Kelun-Biotech ADC Drug Reduces Death Risk by One-Third in Advanced Endometrial Cancer, Phase 3 Trial Shows

An experimental antibody-drug conjugate (ADC) from Merck and China’s Kelun-Biotech has achieved a significant milestone in advanced endometrial cancer. In a Phase 3 trial, the therapy reduced the risk of death by one-third compared to standard treatment, underscoring its potential as a new option for patients with limited alternatives. The drug targets a specific protein on cancer cells, delivering a potent cytotoxic payload directly to tumors. The results mark a major advance for endometrial cancer, which has seen few breakthroughs in recent years. Advanced or recurrent disease carries a poor prognosis, and current treatments often provide only modest benefit. The one-third reduction in mortality represents a clinically meaningful improvement that could reshape treatment guidelines if confirmed by regulators. For Merck, the data strengthen its growing oncology portfolio, while Kelun-Biotech gains validation for its ADC platform. The collaboration highlights the increasing role of Chinese biotech in global drug development. Analysts note that positive Phase 3 data could accelerate regulatory submissions in the U.S., Europe, and China. With detailed results expected at a medical meeting, the oncology community will watch closely for subgroup analyses and safety data. If approved, this ADC could become a new standard of care, offering hope to thousands of women diagnosed with advanced endometrial cancer each year.